The long-acting, injectable antipsychotic Invega Sustenna (paliperidone palmitate), which is given monthly, was found to be effective for six months longer than oral antipsychotics commonly prescribed for schizophrenia, according to a study conducted by the drug’s manufacturer, Janssen.
The PRIDE (Paliperidone Palmitate Research In Demonstrating Effectiveness) study enrolled 444 people in a 15-month, prospective, randomized, open-label, active-controlled study. Patients were randomly given either Invega Sustenna (78–234mg) or one of seven flexibly-dosed, common daily oral antipsychotics: aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone.
The primary endpoint was time to first treatment failure or relapse. Invega Sustenna delayed relapse for a median of 416 days, compared to a median of 226 days with oral antipsychotics, according to study results published The Journal of Clinical Psychiatry.
Its obvious that an injectable is going to last longer. What you don’t understand is that these drugs can put you through a really bad time. @SzAdmin you don’t take drugs yet you push them, if only you would know the truth for some inderviduals that they are very unpleasant.